Paraguay Medical Device Post-Market Compliance: Tecnovigilancia Reports and Registration Renewal (Article 12(c))

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

  1. Article 12, inc. c): the renewal dossier must include a tecnovigilancia report of national or international origin (Informe de Reportes de Tecnovigilancia de origen nacional o internacional).
  2. This is the only provision of Resolution 226/2024 that writes post-market vigilance into the conditions for renewing a registration, and it is a structural feature that distinguishes Paraguay from most other Latin American markets.
  3. The report may come from domestic or international sources, which means that vigilance records generated by the manufacturer on a global basis can be accepted.
  4. Because the certificate is valid for 10 years, the vigilance record must cover the entire holding period in order to satisfy the renewal requirement.

Renewal reviewers read item c) as a continuity test: the report demonstrates that between grant and renewal, someone was watching the product. That is why gaps matter more than volume, and a sparse but continuous record outranks a rich but interrupted one.

2. Legal basis

InstrumentNumber / referenceDateProvisions
Resolution establishing the requirements for market authorization of medical devicesResolución DINAVISA N° 226/20242024-08-27; Article 36: in force as of 2024-09-16Article 12, inc. c)
Law on the powers, duties and structure of DINAVISALey N° 6788/20212021Article 5, inc. b) (legal basis for vigilance-related regulations)

The renewal condition sits on a two-layer foundation. Resolution 226/2024 places the tecnovigilancia report in the renewal dossier through Article 12, inc. c), while Law 6788/2021, which created and structures DINAVISA as the national sanitary surveillance authority, supplies the general mandate for vigilance regulation through Article 5, inc. b). Read together, they show that the renewal requirement is not an administrative invention of the registration manual but an expression of the statutory mission of the authority itself.

The vigilance layer is deliberately positioned inside the registration framework rather than beside it. Where many jurisdictions keep vigilance obligations in a separate post-market chapter enforced by sanctions alone, Paraguay attaches a concrete deliverable, the report, to the renewal event itself. This design converts an abstract duty into a dated, auditable artifact: at each ten-year renewal, the authority can inspect the vigilance history of the product in a single document, and the holder can prove, by production of that document, that its post-market system was alive for the whole cycle.

3. Expert insights

Insight one: item c) upgrades vigilance from a compliance duty into a qualification for holding the certificate. In most markets, vigilance obligations exist independently of the registration certificate, and breaching them leads to sanctions. Paraguay writes the vigilance report into the renewal list, which makes the vigilance record a mandatory renewal document. Without records, the renewal dossier is incomplete, regardless of whether any adverse event ever occurred. This inversion is easy to underestimate: a company that treats vigilance as a dormant obligation, to be activated only when an incident happens, will arrive at renewal with an empty file and no legitimate way to fill it retroactively.

Insight two: accepting international reports lowers the duplicated cost of multi-country programs. The provision expressly refers to reports de origen nacional o internacional. A manufacturer can use its global vigilance system, such as the records generated under ISO 13485 and its post-market surveillance procedures, for the Paraguay renewal, without building a separate local vigilance archive from zero. The corollary is that the channel through which vigilance information flows from the manufacturer to the certificate holder must be unobstructed. Where the holder is a local importer or distributor with no direct access to the manufacturer’s quality system, the absence of a contractual information flow becomes a renewal risk in its own right.

Insight three: the required time span of the report matches the 10-year validity. Certificates are renewed in ten-year cycles, and the vigilance record should cover those same ten years. Continuity is most easily broken when the certificate holder or the vigilance responsible person changes mid-cycle, because records end up split between organizations or stored in systems the successor cannot access. This is the classic risk point of multi-SKU, long-cycle portfolios: each individual transfer looks trivial, but an unbroken documentary chain across a decade requires deliberate handover procedures at every change.

4. Practical recommendations

  1. Open the vigilance archive in the year the certificate is granted and file it annually, without waiting for renewal to approach. An annual filing rhythm turns the eventual renewal report into a simple consolidation exercise.
  2. Write the mutual obligation and the deadlines for transmitting vigilance information between manufacturer and certificate holder into the distribution agreement or the holder agreement, so the flow of records does not depend on goodwill.
  3. Keep both local and international vigilance records in the archive, and submit them under Article 12, inc. c) at renewal. Maintaining both streams protects the dossier if either source is questioned during review.
  4. Whenever the certificate holder or the vigilance responsible person changes, execute a formal handover of the vigilance archive with a written record, so the documentary chain across the ten-year cycle remains verifiable.

The annual archiving rhythm recommended above has a second benefit beyond renewal readiness: it produces, year by year, the evidence that would be needed if DINAVISA raised vigilance questions during an inspection under Article 15 of the same resolution. A maintained archive answers such questions in minutes, while a reconstructed one invites doubt.

For portfolios that include products obtained by acquisition or transferred between holders, the continuity requirement deserves special attention: records created under a previous holder remain part of the vigilance history of the product, and the receiving party should insist on receiving the complete archive as a condition of the transfer, because gaps created before the transfer still surface at the next renewal.

5. Verification checklist

  • □ The vigilance archive has been kept annually since the year of certification
  • □ The obligation to transmit vigilance information between manufacturer and holder is written into agreements
  • □ Both local and international vigilance records are preserved
  • □ A documented handover of the vigilance archive was executed at every personnel change
  • □ The renewal list includes the report required by Article 12, inc. c)

Regulatory information verified as of October 29, 2026.

GRZAN provides registration and post-market compliance support for medical device manufacturers, importers and authorized representatives in Paraguay. For assistance with tecnovigilancia documentation, renewal planning or any other regulatory matter, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail